Download
s00432-021-03759-4.pdf 690,04KB
WeightNameValue
1000 Titel
  • Clinical efficacy and safety of oral and intravenous vitamin C use in patients with malignant diseases
1000 Autor/in
  1. Hoppe, Catalina |
  2. Freuding, Maren |
  3. Büntzel, Jens |
  4. Münstedt, Karsten |
  5. Hübner, Jutta |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-08-17
1000 Erschienen in
1000 Quellenangabe
  • 147(10):3025-3042
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00432-021-03759-4 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397678/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Vitamin C, also called ascorbic acid, is a water-soluble antioxidant and free radical scavenger. It is required in the body for numerous metabolic functions and is involved in the development of proteins and connective tissue.!##!Methods!#!In April 2020, a systematic search was carried out on five electronic databases (Medline, Embase, Cochrane, Cinahl, PsycINFO) to find studies on the use, efficacy and safety of a complementary therapy with vitamin C in oncological patients.!##!Results!#!Out of the initial 23,195 search results, 21 studies with 1961 patients were included in this review. Five of the included studies (n = 417) were randomized controlled trials (RCTs). The remaining 16 studies belonged to a lower class of evidence. The patients who were treated with vitamin C suffered from various malignant diseases, some in an advanced and palliative stage. Vitamin C was applied intravenously or orally. It was either the only treatment or was combined with chemo- or radiotherapy. Endpoints included the development of the disease-related symptoms, quality of life, mortality, progression-free survival and safety of vitamin C. The studies were of moderate quality and showed either no effect of vitamin C or a positive trend, although this has rarely been statistically proven in group comparisons. No or only slight side effects with both oral and intravenous administration of vitamin C were reported.!##!Conclusion!#!Oral intake of vitamin C does not appear to have any effect in patients with malignancies. Data are heterogeneous for intravenous administration. There are no RCTs with statistical group comparisons.
1000 Sacherschließung
lokal Complementary medicine
lokal Cancer
lokal Humans [MeSH]
lokal Safety
lokal Administration, Oral [MeSH]
lokal Review – Clinical Oncology
lokal Antioxidants/administration
lokal Neoplasms/drug therapy [MeSH]
lokal Prognosis [MeSH]
lokal Injections, Intravenous [MeSH]
lokal Vitamin C
lokal Ascorbic Acid/administration
lokal Ascorbic acid
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-5512-5746|https://frl.publisso.de/adhoc/uri/RnJldWRpbmcsIE1hcmVu|https://frl.publisso.de/adhoc/uri/QsO8bnR6ZWwsIEplbnM=|https://frl.publisso.de/adhoc/uri/TcO8bnN0ZWR0LCBLYXJzdGVu|https://frl.publisso.de/adhoc/uri/SMO8Ym5lciwgSnV0dGE=
1000 Hinweis
  • DeepGreen-ID: 4d9c2a21d3e140f389e5ecb78bd4e9f3 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6449814.rdf
1000 Erstellt am 2023-05-09T10:15:05.366+0200
1000 Erstellt von 322
1000 beschreibt frl:6449814
1000 Zuletzt bearbeitet 2023-10-21T01:55:42.625+0200
1000 Objekt bearb. Sat Oct 21 01:55:42 CEST 2023
1000 Vgl. frl:6449814
1000 Oai Id
  1. oai:frl.publisso.de:frl:6449814 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source